Loading…
SAB Biotherapeutics, Inc. is projected to rise to $5.17 by 2027, a +35% move from its current price of $3.82. SABS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $3.70 | $3.82 | $3.94 | -0.04% |
| Jul 15 | $3.65 | $3.82 | $3.99 | -0.08% |
| Jul 16 | $3.61 | $3.82 | $4.03 | -0.12% |
| Jul 17 | $3.58 | $3.81 | $4.06 | -0.16% |
| Jul 18 | $3.55 | $3.81 | $4.09 | -0.19% |
| Jul 19 | $3.53 | $3.81 | $4.12 | -0.23% |
| Jul 20 | $3.50 | $3.81 | $4.14 | -0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.50 | $3.81 | $4.14 | -0.27% |
| Week 2 | $3.38 | $3.80 | $4.28 | -0.54% |
| Week 3 | $3.28 | $3.79 | $4.38 | -0.81% |
| Week 4 | $3.20 | $3.78 | $4.47 | -1.08% |
| Week 5 | $3.13 | $3.77 | $4.54 | -1.35% |
| Week 6 | $3.06 | $3.76 | $4.61 | -1.62% |
| Week 7 | $3.00 | $3.75 | $4.68 | -1.89% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its work centers on advancing antibody-based therapies to treat complex immune-related conditions and infections.
Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. This program represents a key focus within its clinical pipeline as the company advances through midstage testing.
The company was founded in 2014 and is headquartered in Miami Beach, Florida. These details anchor the organization within the healthcare sector and its strategic U.S. clinical development footprint.
SAB Biotherapeutics, Inc. (SABS) is currently trading at $3.90 and has a market cap of $298.21M. The share price and market capitalization place the company as a smaller-cap healthcare issuer with a global clinical-stage focus.
It is ranked 3511 in market capitalization among listed assets, reflecting its size within the market landscape.
The price outlook, as reflected by the year-by-year forecast, shows expanding average prices across multiple years, with 2026 expected to average $3.90 and higher levels anticipated toward the end of the forecast horizon. The trajectory includes a sequence of rising averages and notable upside in longer horizons.
These figures represent estimates and are not guarantees, but they provide a framework for potential longer-term appreciation based on the provided forecast series.
A major floor 20.9% below — a decisive break under it would weaken the trend.
The nearest floor, 13.4% below — buyers have tended to step in here.
The nearest ceiling, 4.7% above — a clean break opens room to run.
A major ceiling 20.2% above — clearing it would confirm fresh momentum.
Key SABS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SABS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.87 | Sell | $3.87 | Sell |
| MA 10 | $3.88 | Sell | $3.86 | Sell |
| MA 20 | $3.82 | Sell | $3.81 | Buy |
| MA 50 | $3.71 | Buy | $3.76 | Buy |
| MA 100 | $3.79 | Buy | $3.73 | Buy |
| MA 200 | $3.62 | Buy | $3.55 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.22 | Neutral |
| Stoch RSI (14) | 17.24 | Buy |
| CCI (20) | -0.29 | Neutral |
| Williams %R (14) | -73.68 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -1.29 | Sell |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 26.32 | Neutral |
| TRIX (15) | 0.26 | Buy |
| Awesome (5,34) | 0.17 | Buy |
| Ultimate (7,14,28) | 43.47 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 3.86 | Sell |
| ADX (14) | 11.15 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture shows bullish sentiment with RSI(14) at 60 and trend leadership implied by the near-term indicators. The 50-day simple moving average sits at $3.69 while the 200-day simple moving average is at $3.48, illustrating a constructive near-term slope.
Support is indicated at $3.31 and resistance at $4.11, framing a modest upside path within the current trading range. The 30-day price range spans from $2.94 to $5.17, highlighting a broad swing in the recent window.
Annualized volatility is 80, underscoring meaningful near-term risk associated with the stock's price movements while the trend remains tilted toward positive momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.31 | $3.82 | $5.01 | 0% | Neutral | |
| $4.06 | $5.17 | $7.01 | +35% | Bullish | |
| $5.12 | $6.74 | $9.53 | +77% | Bullish | |
| $4.99 | $6.76 | $9.87 | +77% | Bullish | |
| $5.46 | $7.57 | $11.36 | +98% | Bullish | |
| $5.93 | $8.41 | $12.93 | +120% | Bullish | |
| $5.59 | $8.09 | $12.71 | +112% | Bullish | |
| $6.33 | $9.34 | $14.95 | +144% | Bullish | |
| $7.48 | $11.26 | $18.33 | +195% | Bullish | |
| $8.57 | $13.13 | $21.73 | +244% | Bullish | |
| $10.13 | $16.84 | $29.85 | +341% | Bullish | |
| $20.03 | $38.43 | $75.20 | +906% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.31 | $3.82 | $4.63 | +0.00% |
| August 2026 | $3.17 | $3.75 | $4.58 | -1.75% |
| September 2026 | $3.09 | $3.69 | $4.55 | -1.76% |
| October 2026 | $3.21 | $3.86 | $4.82 | +4.64% |
| November 2026 | $3.27 | $3.96 | $4.99 | +2.68% |
| December 2026 | $3.24 | $3.95 | $5.01 | -0.39% |
Click any year to see its month-by-month SABS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SABS is projected to trade between $3.31 and $5.01, averaging $3.82 — a potential gain of 0% from today's $3.82. Price action looks broadly range-bound.
SAB Biotherapeutics, Inc.'s 2027 outlook centres on $5.17, within a $4.06 to $7.01 range. That is up +35% on the projected 2026 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, SABS could reach as high as $9.53, with a base case around $6.74 and support toward $5.12 — roughly +77% from $3.82. Momentum favours further upside here.
Expect SABS to range from $4.99 to $9.87 through 2029. The $6.76 average target implies a +77% move from current prices. That is up 0% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The SABS price prediction for 2030 points to an average of $7.57 (low $5.46, high $11.36) — a potential gain of +98% on today's $3.82. Momentum favours further upside here.
In 2031, SABS is projected to trade between $5.93 and $12.93, averaging $8.41 — a potential gain of +120% from today's $3.82. That is up +11% on the projected 2030 average. Buyers look set to stay in control over this stretch.
SAB Biotherapeutics, Inc.'s 2032 outlook centres on $8.09, within a $5.59 to $12.71 range. That is -4% versus the projected 2031 average. That marks a +112% change versus current levels. Momentum favours further upside here.
By 2033, SABS could reach as high as $14.95, with a base case around $9.34 and support toward $6.33 — roughly +144% from $3.82. Buyers look set to stay in control over this stretch.
Expect SABS to range from $7.48 to $18.33 through 2034. The $11.26 average target implies a +195% move from current prices. That is up +21% on the projected 2033 average. Momentum favours further upside here.
The SABS price prediction for 2035 points to an average of $13.13 (low $8.57, high $21.73) — a potential gain of +244% on today's $3.82. Buyers look set to stay in control over this stretch.
In 2040, SABS is projected to trade between $10.13 and $29.85, averaging $16.84 — a potential gain of +341% from today's $3.82. That is up +28% on the projected 2035 average. Momentum favours further upside here.
SAB Biotherapeutics, Inc.'s 2050 outlook centres on $38.43, within a $20.03 to $75.20 range. That is up +128% on the projected 2040 average. That marks a +906% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in SABS today (≈ 261.780105 SABS) could be worth
$10,058.97
+$9,058.97 (+906%) by 2050 · US Dollar
Based on the average projected SABS price of $38.43 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SABSwould be worth at today's price.
$1,000 invested in SABS on Jul 10, 2025 (≈ 400 SABS) would be worth
$1,528
+$528 (+52.8%) today · 1.53× · US Dollar
Based on a SABS entry price of $2.5 vs. today's $3.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.92 | $974.49 | -2.6% |
| 1 month ago | $3.31 | $1,154.08 | +15.4% |
| 3 months ago | $3.75 | $1,018.67 | +1.9% |
| 6 months ago | $3.74 | $1,021.39 | +2.1% |
| 1 year ago | $2.5 | $1,528 | +52.8% |
| All time (5.0y) ago | $99.34 | $38.45 | -96.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SABS forecast.
Our base-case forecast reaches $7.60 around 2031.
Implied market cap at $7.60: $581.13M
The multi-year forecast shows a clear path of growth across the years, with the average price advancing from $3.90 in 2026 to higher levels over time. Notable milestones include an average of $8.11 in 2030, $15.26 in 2040, and $39.81 in 2050, with corresponding forward-looking upside.
The forecast implies ROI progression from 0 in 2026 to 108 in 2030, 291.4 in 2040, and 920.8 in 2050, with sentiment turning bullish from 2027 onward. These figures illustrate substantial potential upside in longer horizons, tempered by the inherent uncertainty of long-range projections.
Investors should consider the long-term outlook as estimates rather than guarantees, recognizing that market dynamics, regulatory developments, and clinical outcomes can influence actual results and that near-term volatility can persist despite a bullish longer-term trajectory.
Tap a question to reveal the answer.
The 2030 average forecast is $8.11 with an ROI of 108 and sentiment BULLISH.
The forecast shows rising averages and positive ROIs from 2027 onward, with 2030–2050 ROIs of 108, 291.4, and 920.8 respectively, but 2026 is neutral with an avg of $3.90 and ROI of 0; these are estimates, not guarantees.
Yes, the 2050 max forecast is $89.04, which exceeds $50, though this depends on future conditions aligning with the forecast.
Current price is $3.90 with a 30-day range from $2.94 to $5.17, support at $3.31, and resistance at $4.11.
The 2026 min is $3.31, avg is $3.90, max is $5.47, with ROI 0 and sentiment NEUTRAL.
SAB Biotherapeutics, Inc. Community Discussion
0Share your SAB Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.